<DOC>
	<DOCNO>NCT00637403</DOCNO>
	<brief_summary>To determine pharmacokinetics safety megestrol acetate single oral 300 mg dose megestrol acetate concentrate suspension healthy subject , subject vary degree renal impairment</brief_summary>
	<brief_title>Effect Renal Impairment Pharmacokinetics , Safety Megestrol Acetate Concentrated Suspension</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Healthy Subjects Normal Renal Function 1 . BMI ≥18 kg/m2 ≤35 kg/m2 2 . Females childbearing potential must use adequate reliable method contraception . Postmenopausal females must postmenopausal ≥1 year elevate serum FSH 3 . Able provide write informed consent 4 . Normal renal function , define estimate creatinine clearance ( CLcr ) &gt; 80 mL/min screen Subjects Mild , Moderate , Severe Renal Impairment ESRD Meet inclusion criterion 1 3 healthy subject follow criterion : 1 . Renal impairment define creatinine clearance &lt; 80 mL/min determine use CockroftGault formula . Subjects group accord degree renal dysfunction : mild ( CLcr = &gt; 50 ≤80 mL/min ) , moderate ( CLcr = &gt; 30 ≤50 mL/min ) , severe ( CLcr = ≤30 mL/min ) 2 . Renal Impairment subject must evidence stable renal impairment . Defined CLcr value within 25 % 2 separately measure serum creatinine clearance use CockroftGault formula 3 . ESRD subject require hemodialysis least 3 month 4 . Subjects renal impairment ESRD may clinical laboratory test result deviation judge Investigator consistent renal condition subject additional clinical significance study 5 . Subjects renal impairment ESRD , must stable underlying medical condition least 90 day prior start study participation 6 . Renal impaired subject may smoke 5 cigarette per day Healthy Subjects Normal Renal Function 1 . Clinically significant ( history active ) cardiac , hepatic , renal , pulmonary , endocrine , neurological , infectious , gastrointestinal , hematologic , oncologic , psychiatric disease could put subject increase risk could interfere objective study 2 . Presence screen laboratory value outside range normal value deem clinically significant Investigator 3 . Use prescription drug within 14 day study start , nonprescription drug within 7 day study start , need concomitant medication study 4 . Use drug herbal product know inhibit induce liver enzymes involved drug metabolism ( CYP P450 ) within 30 day prior 1st dose 5 . History allergic reaction serum sickness drug drug metabolites 6 . Whole blood donation within 56 day prior first MACS dose plasma donation within 7 day prior first MACS dose 7 . Positive test HIV antibody hepatitis B surface antigen ( positive HIV hepatitis C antibody ESRD subject acceptable ) 8 . Presence drug abuse and/or alcohol 9 . Participation another investigational drug study within 30 day prior first MACS dose 10 . History recent drug abuse alcohol addiction past 2 year 11 . Pregnant breastfeed 12 . Consumption grapefruit contain food beverage within 7 day prior first MACS dose 13 . History recurrent thromboembolic event , thromboembolic event past three month , still receive longterm anticoagulation thromboembolism Subjects Mild , Moderate , Severe Renal Impairment ESRD Excluded subject meet exclusion criterion 4 13 healthy subject follow criterion : 1 . Unstable disease define concurrent medical condition change significantly within 90 day 2 . Changes concomitant medication within 14 day prior first dose administration expect change study participation 3 . Subjects renal transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>renal impairment</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>megestrol acetate</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>renal dialysis</keyword>
	<keyword>kidney failure , chronic</keyword>
	<keyword>renal insufficiency</keyword>
	<keyword>Megace ES</keyword>
</DOC>